Skip to main content
Erschienen in: Pathology & Oncology Research 2/2012

01.04.2012 | Research

Targeting MET by Tyrosine Kinase Inhibitor Suppresses Growth and Invasion of Nasopharyngeal Carcinoma Cell Lines

verfasst von: Patrick C. Lau, Elaine Y. Wong

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Nasopharyngeal carcinoma (NPC) represents a common cancer in endemic areas with high invasive and metastatic potential. It is now known that the HGF-MET signaling pathway plays an important role in mediating the invasive growth of many different types of cancer, including head and neck squamous cell carcinoma. HGF has been shown to stimulate NPC cell growth and invasion in cell line model. The current study aims at demonstrating the effect of MET inhibition by small molecule tyrosine kinase inhibitor PHA665752 on the growth and invasive potential of NPC cell lines. NPC cell lines were used for immunohistochemistry for the MET protein, as well as western blot analysis on MET together with its downstream cascade signaling proteins after treatment with PHA665752. The effect on cell growth, migration and invasion after PHA665752 treatment was also studied. MET inhibition by PHA665752 resulted in highly significant inhibition on NPC cell growth, migration and invasion in vitro. Down-regulation of phospho-MET, phospho-Akt, phospho-MAPK, phospho-STAT3, cyclin D1, β-catenin and PCNA was detected in NPC cells after PHA665752 treatment. MET inhibition with tyrosine kinase inhibitor resulted in suppression of NPC cell growth and invasive potential via down-regulation of a variety of signaling onco-proteins. MET is an important therapeutic target for NPC that warrants further studies and clinical trials.
Literatur
1.
Zurück zum Zitat Zur Hausen H, Schulte-Holthausen H, Klein G et al (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056–8PubMedCrossRef Zur Hausen H, Schulte-Holthausen H, Klein G et al (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056–8PubMedCrossRef
2.
Zurück zum Zitat Tao Q, Chan ATC (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9:1–24PubMedCrossRef Tao Q, Chan ATC (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9:1–24PubMedCrossRef
3.
Zurück zum Zitat Lee N, Xia P, Quivey JM et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12–22PubMedCrossRef Lee N, Xia P, Quivey JM et al (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12–22PubMedCrossRef
4.
Zurück zum Zitat Kam MKM, Teo PML, Chau RMC et al (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. Int J Radiat Oncol Biol Phys 60:1440–50PubMedCrossRef Kam MKM, Teo PML, Chau RMC et al (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. Int J Radiat Oncol Biol Phys 60:1440–50PubMedCrossRef
5.
Zurück zum Zitat Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56PubMedCrossRef Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64:47–56PubMedCrossRef
6.
Zurück zum Zitat Jeffers M, Rong S, Vande Woude GF (1996) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74:505–13PubMedCrossRef Jeffers M, Rong S, Vande Woude GF (1996) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74:505–13PubMedCrossRef
7.
Zurück zum Zitat Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Bio 4:915–25CrossRef Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Bio 4:915–25CrossRef
8.
Zurück zum Zitat Lau PC, Chan AT (2011) Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. Anticancer Drugs 22:665–73PubMedCrossRef Lau PC, Chan AT (2011) Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. Anticancer Drugs 22:665–73PubMedCrossRef
9.
Zurück zum Zitat Horikawa T, Sheen T, Takeshita H et al (2001) Induction of c-Met proto-oncogene by Epstein-Barr Virus Latent Membrane Protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159:27–33PubMedCrossRef Horikawa T, Sheen T, Takeshita H et al (2001) Induction of c-Met proto-oncogene by Epstein-Barr Virus Latent Membrane Protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159:27–33PubMedCrossRef
10.
Zurück zum Zitat Qian CN, Guo X, Cao B et al (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62:589–96PubMed Qian CN, Guo X, Cao B et al (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62:589–96PubMed
11.
Zurück zum Zitat Zhou HY, Wan KF, Ip CK et al (2008) Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 582:3415–22PubMedCrossRef Zhou HY, Wan KF, Ip CK et al (2008) Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK. FEBS Lett 582:3415–22PubMedCrossRef
12.
Zurück zum Zitat Xie LQ, Bian LJ, Li Z et al (2010) Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol 17:1927–36PubMedCrossRef Xie LQ, Bian LJ, Li Z et al (2010) Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol 17:1927–36PubMedCrossRef
13.
Zurück zum Zitat Glaser R, Zhang HY, Yao KT et al (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 86:9524–8PubMedCrossRef Glaser R, Zhang HY, Yao KT et al (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 86:9524–8PubMedCrossRef
14.
Zurück zum Zitat Lo AK, Lo KW, Tsao SW et al (2006) Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8:173–80PubMedCrossRef Lo AK, Lo KW, Tsao SW et al (2006) Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8:173–80PubMedCrossRef
15.
Zurück zum Zitat Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–9PubMedCrossRef Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–9PubMedCrossRef
Metadaten
Titel
Targeting MET by Tyrosine Kinase Inhibitor Suppresses Growth and Invasion of Nasopharyngeal Carcinoma Cell Lines
verfasst von
Patrick C. Lau
Elaine Y. Wong
Publikationsdatum
01.04.2012
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9452-1

Weitere Artikel der Ausgabe 2/2012

Pathology & Oncology Research 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.